CIIS - Documentos de Conferências / Conference Objects
URI permanente para esta coleção:
Navegar
Entradas recentes
- Triage systems in palliative care - a scoping reviewPublication . Gaudêncio, Margarida; Gonçalves, Florbela; Capelas, Manuel Luís
- Equity of access: the referral process in palliative care – preliminary data from a scoping reviewPublication . Ramos, Andreia; Marinho, Susana; Capelas, Manuel Luís
- Economic cost of avoidable emergency care for palliative patients: the national reality in PortugalPublication . Afonso, Tânia dos Santos; Santos, Inês Filipa de Matos; Martins, Lurdes; Capelas, Manuel Luís
- Health-Related Suffering (HRS) in people with palliative care needs: Portugal 1980-2022Publication . Capelas, Manuel Luís; Santos, Inês Filipa de Matos; Nunes, Sofia; Mateus, Ana Francisca; Afonso, Tânia dos Santos
- Place of death and palliative care access in Portuguese dementia patients: a trend analysisPublication . Santos, Inês Filipa de Matos; Afonso, Tânia dos Santos; Nunes, Sofia; Mateus, Ana Francisca; Capelas, Manuel Luís
- Work productivity and indirect cost savings of atogepant versus topiramate: results from the TEMPLE trialPublication . Terán, J. Díaz de; Gandhi, P.; Guo, H.; Haile, F.; Nagy, K.; Carr, K.; Versijpt, J.; Gil-Gouveia, R.; Buse, D.; Lipton, R.Background and aims: Using the Work Productivity and Activity Impairment (WPAI): Migraine, we contrasted presenteeism, absenteeism, overall work productivity, and indirect cost savings of participants who received atogepant versus topiramate for the preventive treatment of migraine. Methods: TEMPLE was a phase 3b, randomized, multicenter, double-blind (DB), double-dummy, active-controlled trial to evaluate tolerability, safety, and efficacy of atogepant compared with topiramate for the preventive treatment of migraine. WPAI:Migraine was evaluated at each 4-week time point during the 24-week DB period. An excel-based cost calculator used WPAI data to calculate the per-patient-per-year (PPPY) work productivity cost by multiplying the percent overall work productivity loss, weeks per year, standard weekly full-time work hours (40), and the average hourly wage in Canada, Portugal, United Kingdom, and United States. Productivity benefit from using atogepant was calculated as the difference between atogepant and topiramate productivity loss PPPY. Results: Based on WPAI data from TEMPLE, atogepant demonstrated greater improvements in presenteeism and overall work productivity (Figures 1 and 2), and lower absenteeism and activity impairment versus topiramate. The cost calculator using overall work productivity data demonstrated atogepant provided greater productivity benefits and indirect cost savings compared with topiramate across all 4 countries (Table 1). Conclusion: Atogepant consistently demonstrated greater improvement compared to topiramate across all four WPAI domains. Using TEMPLE WPAI data, atogepant demonstrated work productivity benefit compared to topiramate in Canada, Portugal, UK, and United States.
- Impact of trialing multiple triptans on work productivity and indirect costs in employed individuals with migraine: CaMEO-I study findingsPublication . Versijpt, J.; Fanning, K.; Gandhi, P.; Chalermpalanupap, N.; Leroux, E.; Jacob, P.; Carr, K.; Buse, D.; Gil-Gouveia, R.Background and aims: Individuals with migraine may experience suboptimal efficacy or adverse events with triptans, potentially contributing further to disease burden, particularly among working populations. CaMEO-I, a multi-country, crosssectional, observational survey study, assessed the burden of migraine internationally. This analysis evaluates the impact of the number of triptans trialed on work productivity loss and annual indirect costs, among employed individuals with migraine. Methods: This post hoc analysis included employed adults with complete Work Productivity and Activity Impairment (WPAI) data from CaMEO-I, stratified by number of triptans trialed: current user (0), 1, 2, and ≥3. Median work impairment and indirect costs were measured via WPAI. Indirect costs were estimated in respondents' local currency, scaled using countryspecific working weeks, and adjusted for inflation to October 2025 values. Results: Here, data from US (n=565), UK (n=506), and Germany (n=571) are reported; results for all six countries are in the complete analysis. Median WPAI: overall work productivity Impairment ranged from 50.0–85.8%, increasing with the number of triptans trialed (Figure 1). Parallel trends were observed in median annual indirect costs. Those who trialed ≥3 triptans generally demonstrated the highest indirect costs: $32,927 (US), £18,964 (UK), and €24,716 (Germany). Across all countries, indirect cost generally increased across response strata, with most countries showing the greatest cost burden among individuals who trialed ≥3 triptans (Figure 2). Conclusion: Insights from the CaMEO-I study suggest that among employed individuals with migraine, trialing multiple triptans is associated with increases in both work productivity loss and indirect costs, across multiple countries.
- Effect of atogepant on cognitive function following acute treatment of migraine across multiple attacks: results from the ECLIPSE trialPublication . Van Dycke, A.; Ahmadyar, G.; Brand-Schieber, E.; Castro, C.; Ornello, R.; Luo, L.; Pozo-Rosich, P.; Reuter, U.; Carr, K.; Gil-Gouveia, R.Background and aims: Atogepant is approved for the preventive treatment of migraine in adults and has recently demonstrated its efficacy and safety for the acute treatment of migraine. This analysis evaluated the impact of atogepant 60mg administered as needed (PRN) for acute treatment of migraine on cognitive function assessed by the ability to think clearly. Methods: ECLIPSE was a double-blind (DB), placebo-controlled, multiple-attack, crossover trial evaluating atogepant's efficacy, safety, and tolerability for acute migraine treatment. Adults with 2–8 monthly moderate-to-severe attacks were randomised to receive atogepant for three qualifying attacks and placebo for one attack during the up to 16-week DB period. Cognitive function scale is a single-item, patient-reported questionnaire measuring participants' difficulty in ability to think clearly, rated from 0 (not difficult at all) to 3 (very difficult). The proportion of participants achieving the ability to think clearly at 2-, 4-, and 8-hours postdose across attacks 1–4 was an additional (exploratory) efficacy endpoint. Data for atogepant and placebo are presented with nominal p-values. Results: Atogepant treatment resulted in a nominally significant higher proportion of participants achieving the ability to think clearly compared with placebo as early as 2-hours postdose in the first treated attack (OR: 1.78, Figure 1); this effect increased over time through 4- and 8-hours postdose (OR: 3.39, 3.73, respectively; Figure 1). A similar reliable response was observed across attacks 2–4 (Figure 2). Conclusion: A greater proportion of participants treated with atogepant achieved the ability to think clearly compared to placebo as early as 2-hours and up to 8-hours postdose across multiple attacks.
- University students' perceptions of the impact of service-learning on the final beneficiariesPublication . Ribeiro, Luísa Mota; Miranda, Francisca; Oliveira, Ana; Correia, Maria; Ribeiro, Célia; Peixoto, Ricardo; Dias, Paulo César; Themudo, Carmo; Costa, Helena Gil da; Costa, Joana Cunha e; Silva, Marta; Pona, Rita Paiva eService-learning (SL) is a methodology that contributes to outcomes in students' academic learning, civic participation, and personal growth (Bringle & Clayton, 2021). There are several studies that analyze the impact of SL on university students (e.g., Allen et al., 2021; Fong et al., 2021; Samino García, 2023; Smith et al., 2021). However, research focused on the impact of SL on final beneficiaries is still scarce. The present study aimed to analyze university students’ perceptions regarding the perceived impact of SL experiences on the final beneficiaries. It may be challenging to directly access the final beneficiaries to assess the impact or there might be ethical restrictions on collecting sensitive data from them. We believe that students’ perceptions can provide valuable insights into the perceived impact on the final beneficiaries, considering their direct involvement in the activities and their deeper understanding of the changes and benefits they observe. Moreover, adopting this research approach allow us to give voice to university students, recognizing the significance of their perceptions and interpretations as active and reflective participants. This study involved 58 students from Universidade Católica Portuguesa, mostly female (77.6%) and aged between 19 and 61 years (M = 24.11; SD = 8.55). Students were enrolled in different programs (management, nursing, psychology, and social work) and were involved in 9 different SL projects. Most of the students developed SL projects in elderly care home/day care center, but there were also SL projects in daycare/kindergarten/school, institution that supports vulnerable families, community intervention project, foster home, and institution that supports social reinsertion. Thus, the final beneficiaries of the SL projects included elderly people (mostly), children and/or youth, homeless people, vulnerable families, and people with addiction problems. After the conclusion of the SL projects, students were asked to complete an online questionnaire that included an open-ended item about the impact of the projects on the final beneficiaries (“Analyze how the service developed had an impact on the community/final beneficiaries (group of people addressed by the project)”). Data were analyzed using NVIVO. The results point to a perceived positive impact of the SL projects on the final beneficiaries, in several domains, such as: high satisfaction/enthusiasm, improved quality of life, improved health, higher self-esteem, reintegration into society, development of knowledge (e.g., about managing emotions). The results contribute to understand the perceived impact of the SL methodology on the final beneficiaries, a topic that has been understudied in the literature. Practical implications will be discussed, considering practical guidelines for the design and improvement of future SL projects.
- Salivary protein profile as a tool for patient stratification in peri-implantitisPublication . Saavedra, M.; Sousa, S.; Silva, A.; Martins, J. E.; Esteves, E.; Fernandes, M.; Rosa, N.; Correia, M. J.; Barros, M.